The efficacy and safety of rituximab in treating childhood refractory nephrotic syndrome: A meta-analysis

Abstract

Rituximab is considered to be a promising drug for treating childhood refractory nephrotic syndrome. However, the efficacy and safety of rituximab in treating childhood refractory nephrotic syndrome remain inconclusive. This meta-analysis aimed to investigate the efficacy and safety of rituximab treatment compared with other immunosuppressive agents in… (More)
DOI: 10.1038/srep08219

Topics

7 Figures and Tables

Cite this paper

@inproceedings{Zhao2015TheEA, title={The efficacy and safety of rituximab in treating childhood refractory nephrotic syndrome: A meta-analysis}, author={Zhihong Zhao and Guixiang Liao and Yongqiang Li and Shulu Zhou and Hequn Zou}, booktitle={Scientific reports}, year={2015} }